J. Virol. doi:10.1128/JVI.01079-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Inhibition of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein-Mediated Single Cell Lysis by Low-Molecular-Weight Antagonists of Viral Entry
Navid Madani,
Amy M. Hubicki,
Ana Luisa Perdigoto,
Martin Springer,
and
Joseph Sodroski*
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA 02115; Department of Pathology, Division of AIDS, Harvard Medical School, Boston, MA 02115; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115; Department of Biochemical Immunology, Merck & Co., Inc., Rahway, NJ 07065-0900
* To whom correspondence should be addressed. Email:
joseph_sodroski{at}dfci.harvard.edu.
 |
Abstract |
|---|
The coexpression of human immunodeficiency virus (HIV-1) envelope glycoproteins and receptors leads to the lysis of single cells by a process that is dependent upon membrane fusion. This cell lysis was inhibited by low-molecular-weight compounds that interfere with receptor binding or with receptor-induced conformational transitions in the envelope glycoproteins. A peptide, T20, potently inhibited cell-cell fusion but had no effect on single cell lysis mediated by the HIV-1 envelope glycoproteins. Thus, critical events in the lysis of single cells by the HIV-1 envelope glycoproteins occur in intracellular compartments accessible only to small inhibitory compounds.